Medtronic’s Endeavor Stent Hits Primary Endpoint In Pivotal Trial
This article was originally published in The Gray Sheet
Medtronic's Endeavor zotarolimus-eluting stent is as effective as Boston Scientific's Taxus paclitaxel-eluting stent in the ENDEAVOR IV trial, Medtronic announced July 2
You may also be interested in...
Medtronic is confident being the late-comer to the U.S. drug-eluting stent market will not hinder its Endeavor zotarolimus-eluting coronary stent gaining market share
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.